Eric Deutsch

@Edradonc

Chair of radiation oncology & lab. medicine -1-trials

Paris, France
Vrijeme pridruživanja: veljača 2016.

Tweetovi

Blokirali ste korisnika/cu @Edradonc

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Edradonc

  1. 31. sij

    Molecular radiotherapy and innovative therapeutics INSERM1030 unit , kick starter meeting for the new 5 years contract. @université-paris-saclay

    Poništi
  2. 31. sij

    Digital medicine approved in France for lung cancer surveillance. Dr Fabrice Dénis présents his web and phone app at our weekly department round form the theory of chaos to a JAMA paper ...and reimbursement ..

    Poništi
  3. 29. sij

    A Post-doctoral position in Tumor Immunology is available in the Molecular Radiotherapy INSERM U1030 unit at Gustave Roussy Cancer Campus, Paris. One post-doctoral position will be available to study combination of radiotherapy with immunotherapy strategies perfettini@orange.fr

    Poništi
  4. 29. sij

    Physicien médical Gustave Roussy, recherche Physicien Médical (H/F). Il intègrera une équipe composée de 11 physiciens en radiothérapie-curiethérapie, 4 techniciens de contrôle de qualité, 11 dosimétristes et un chef du service de physique.

    Poništi
  5. 27. sij
    Poništi
  6. proslijedio/la je Tweet
    24. sij

    Nice to brainstorm U1030 future projects ⁦⁩ ⁦⁩ ⁦

    Poništi
  7. 20. stu 2019.

    post-doctoral position at IRSN/Gustave Roussy Characterization cell RNAseq of myeloid cells involved in the tumor/healthy tissue radiation-induced response of response after irradiation Contact : fabien.milliat@irsn.fr, Eric.DEUTSCH@gustaveroussy.fr

    Poništi
  8. 9. ruj 2019.
    Poništi
  9. proslijedio/la je Tweet
    17. lis 2018.
    Poništi
  10. proslijedio/la je Tweet
    4. lis 2018.

    Pour en savoir plus sur les travaux de Pierre Golstein et son équipe du Centre d’immunologie de qui ont conduit à l’identification de la protéine 👉

    Prikaži ovu nit
    Poništi
  11. 6. lis 2018.

    Unique opportunity for young MDs and PharmDs specialized in oncology whatever the field 1 one year research and training research @ Gustaveroussy Selection of motivated candidates is already open for the next season! Viviane.MENGUY@gustaveroussy.fr

    Poništi
  12. 20. ruj 2018.

    Enzo Bronte and Jerome Galon discussing future of combined therapies @Immunrad18

    Poništi
  13. proslijedio/la je Tweet
    5. ruj 2018.

    Centrale-Supelec AI expert Nikos Paragios joins the line-up of ImmunoRad Conference in the "Radiomics" session ! Come and discover how medical imaging meets AI. Check our final program and register at /

    Poništi
  14. 4. ruj 2018.

    High quality cancer registries are clearly providing evidence how HPV affects cancer rates and trends.

    Poništi
  15. proslijedio/la je Tweet
    3. kol 2018.

    The 3rd ImmunoRad conference starts in Paris on the 20th of sep, focusing on combinations from basic research to clinical applications. Thanks to and for supporting us!

    Poništi
  16. proslijedio/la je Tweet

    Join SITC members, Drs. Vincenzo Bronte, Lorenzo Galluzzi and Jérôme Galon, at the International Conference on Immunotherapy Radiotherapy Combinations Sept. 20–22 in Paris. Learn more at:

    Poništi
  17. 22. lip 2018.

    Should radioimmunotherapy lead to a change in our radiotherapy regimens ? More details in Raphael Serre et al in press ..

    Poništi
  18. 22. lip 2018.

    Meeting of the phase I center” APHM CLIP” in marseille. Raphael Serre proposes a model for the Immunoligical effective dose www.smartcalculators.omline/ied a step toward an optimization of radio immunotherapy ?

    Poništi
  19. 20. lip 2018.

    Time to register !! The full program of our Immunorad18 conference on Radiotherapy and immunotherapy combinations from basics to clinical application is now available.

    Poništi
  20. 5. lip 2018.

    abscopal responses in TNBC , massive out of the field responses . Very promising , (larger randomized series will have to comfort these data..).. # asco2018

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·